Plain-English translation of NCT07496021 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a 24-week study testing a probiotic medication called to see if it can help slow cognitive decline in people with early Alzheimer's disease. Half of the participants will receive the medication, and half will receive a placebo (a pill with no active ingredient), so researchers can understand whether the treatment actually works. The study is designed to assess both safety and effectiveness.
Current Alzheimer's treatments have limited effectiveness, and researchers are exploring new approaches, including probiotics that may help reduce brain inflammation and amyloid buildup—hallmarks of Alzheimer's disease. This early-stage study aims to determine whether this medication is safe and shows promise for slowing memory loss.
You likely qualify if…
You likely don't qualify if…
Over 24 weeks, you would take either the probiotic medication or a placebo daily. You'll have multiple clinic visits for cognitive testing, brain imaging, blood work, and safety assessments. The study involves detailed memory and thinking tests, as well as a PET scan to monitor amyloid levels in your brain throughout the trial.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
South Korea
Sponsor
CKD Bio Corporation
Enrollment target
~60 participants
Started
February 2026
Primary completion
May 2027
Age range
55 Years – 85 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bisong Kim
Yonsei University Yongin Severance Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.